DekaBank Deutsche Girozentrale Sells 40,000 Shares of CureVac (NASDAQ:CVAC)

DekaBank Deutsche Girozentrale lessened its stake in CureVac (NASDAQ:CVAC) by 31.8% in the 4th quarter, HoldingsChannel.com reports. The firm owned 85,642 shares of the company’s stock after selling 40,000 shares during the period. DekaBank Deutsche Girozentrale’s holdings in CureVac were worth $363,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the stock. Vontobel Holding Ltd. grew its holdings in CureVac by 3.8% during the 1st quarter. Vontobel Holding Ltd. now owns 19,411 shares of the company’s stock worth $381,000 after acquiring an additional 702 shares during the period. Geode Capital Management LLC grew its holdings in shares of CureVac by 0.7% in the 1st quarter. Geode Capital Management LLC now owns 167,202 shares of the company’s stock valued at $1,165,000 after buying an additional 1,188 shares during the period. Citigroup Inc. grew its holdings in shares of CureVac by 10.2% in the 2nd quarter. Citigroup Inc. now owns 13,491 shares of the company’s stock valued at $141,000 after buying an additional 1,253 shares during the period. Royal Bank of Canada grew its holdings in shares of CureVac by 13.0% in the 3rd quarter. Royal Bank of Canada now owns 11,119 shares of the company’s stock valued at $87,000 after buying an additional 1,280 shares during the period. Finally, Marshall Wace LLP grew its holdings in shares of CureVac by 0.5% in the 3rd quarter. Marshall Wace LLP now owns 333,819 shares of the company’s stock valued at $2,629,000 after buying an additional 1,758 shares during the period. Institutional investors own 17.26% of the company’s stock.

Analysts Set New Price Targets

Separately, Guggenheim reissued a “neutral” rating on shares of CureVac in a report on Friday, April 5th.

CureVac Stock Up 0.6 %

Shares of NASDAQ CVAC opened at $2.67 on Wednesday. The company has a quick ratio of 3.41, a current ratio of 3.56 and a debt-to-equity ratio of 0.06. CureVac has a 1-year low of $2.54 and a 1-year high of $12.36. The company has a fifty day moving average price of $3.22 and a 200 day moving average price of $4.33.

CureVac Profile

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza.